Stephanie J Nahas, EAN 2020 – Anti-CGRP mAb Efficacy in Patients ≥60 With Episodic/Chronic Migraine
Stephanie J Nahas (Thomas Jefferson University, Jefferson Headache Center, Philadelphia, PA, USA) kindly took the time to discuss with us pooled findings from phase 3 randomised controlled trials with fremanezumab, an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody treatment, specifically in older patients (≥60 years) with episodic or chronic migraine.
Questions
1. How does the clinical phenotype of migraine differ in patients aged 60 and over compared with that in younger patients? (0:05)
2. What are the main unmet needs in the treatment of episodic or chronic migraine in this patient group? (0:57)
3. How extensively has fremanezumab been studied in this patient group? (2:01)
4. What were the efficacy and safety findings of your pooled analysis? (3:00)
5. Among older patients, which are likely to benefit most from fremanezumab and in whom is it contraindicated? (4:46)
Speaker disclosure: Stephanie J Nahas has served on an advisory board, as a speaker, or as a consultant for Allergan, Amgen/Novartis, Biohaven, electroCore, Eli Lilly, Impel, Supernus, Teva Pharmaceuticals, Theranica, and Zosano.
Support: Interview and filming supported by Touch Medical Media.
Filmed at the 6th Congress of the European Academy of Neurology (EAN) and 1st EAN Virtual Congress, May 2020.
